Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Assessment of cognitive safety in clinical drug development

Authors: Jonathan P. Roiser, Pradeep J. Nathan, Adrian P. Mander, Gabriel Adusei, Kenton H. Zavitz, Andrew D. Blackwell

Abstract:

Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.

Citation:  Jonathan P. Roiser, Pradeep J. Nathan, Adrian P. Mander, Gabriel Adusei, Kenton H. Zavitz, Andrew D.  Blackwell Assessment of cognitive safety in clinical drug development doi:10.1016/j.drudis.2015.11.003

Available online: 22 November 2015

Copyright: © 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/).

Conflict of interest:

Other than A.P.M. and J.P.R., all authors were employees of Cambridge Cognition Ltd at the time of writing. J.P.R. consults for Cambridge Cognition Ltd. P.J.N. is on the editorial board of Drug Discovery Today but was not involved in the review of this manuscript.

Acknowledgements

We thank Kristina Cook for assistance in figure preparation and Rebecca Landy for statistical discussions. This article was supported by Cambridge Cognition Ltd. Employees of the company made substantive intellectual contributions to the manuscript and approved the final version. A.P.M. is funded by the Medical Research Council (grant number G0800860).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024